Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central nervous process, conolidine modulates alternate molecular targets. A Science Advancements review identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://conolidineamagicmorphine13457.mdkblog.com/43845332/the-2-minute-rule-for-conolidin-to-replace-traditional-painkillers